Home | Welcome to Contract Pharma   
Last Updated Wednesday, May 27 2015

Print RSS Feed

Financial Reports: AstraZeneca

By Gil Roth

Published February 6, 2014
AstraZeneca 4Q13

4Q Revenues: $6.8 billion (-6%)

4Q Loss: $524 million (earnings of $1.5 billion in 4Q12)

FY Revenues: $25.7 billion (-8%)

FY Earnings: $2.6 billion (-60%)

Comments: For FY13, AstraZeneca's U.S. revenues fell by 9%, while Rest of World (RoW) revenues fell 4%. Crestor revenues fell by 8% in both 4Q and FY, to $1.5 billion and $5.6 billion, respectively. Onglyza reenues grew 17% in FY to $378 million, but only 6% in 4Q to $93 million. Symbicort sales were up 11% in 4Q to $976 million and 10% in FY to $3.5 billion. Generic pressure erased 39% of Seroquel sales, which dropped from $2.8 billion in FY12 sales to $1.7 billion in FY13. Brilinta sales were $92 million in 4Q, up from $75 million in 3Q13. Sales of Atacand and Seloken/Toprol-XL began to crater from generic exposure. Atacand sales fell 39% in FY to $611 million, while Seloken 4Q sales fell 32% to $170 million. Losec/Prilosec sales fell 28% in FY to $486 million. Nexium sales were flat at $3.9 billion in FY, but generics will enter the U.S. market in 2Q14. The company announced an additional $700 million in restructuring programs, which will lead to cuts of approximately 550 staffers and is projected to result in $300 million in annual benefits. In total, the company's current restructuring will cost $3.2 billion, yield annual benefits of $1.1 billion, and result in layoffs of 5,600 people.

blog comments powered by Disqus

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On